Reclast Lawyers: The incubation period—the time between the entrance of the virus into the body and the initial appearance of symptoms and signs of the disease—of acute HCV is about six to eight weeks; however, it may be as short as two weeks or as long as about five months.
When symptoms of acute hepatitis C do occur, they are usually similar to those that characterize acute hepatitis in general. However, most people with acute hepatitis C experience no symptoms. Only about 25 to 35 percent of individuals with hepatitis C manifest any symptoms at all. Usually, these symptoms are nonspecific and may easily be mistaken as stemming from something unconnected to hepatitis C, such as the flu. Symptoms, if they do occur, may include fatigue, decreased appetite, and weakness. Occasionally, a person may experience a skin rash and/or muscle and joint aches. People with acute hepatitis C become jaundiced approximately 25 percent of the time. It has been shown that people with another liver disease, such as hepatitis B, who become additionally infected with acute hepatitis C, are particularly likely to experience a severe course of acute hepatitis C. Usually, the physical exam of a person with acute hepatitis C appears normal. Occasionally, a physical exam will reveal an enlarged and tender liver, jaundice, and/or a rash.
As mentioned previously, approximately 35,000 new acute hepatitis C infections are estimated to occur each year. However, it is also estimated that only 25 to 30 percent of these newly acquired infections are actually diagnosed. The most likely explanation for this low percentage is that most people with acute hepatitis C are either asymptomatic or have very vague symptoms. Therefore, evaluation by a doctor during the acute stage of this disease is not common. As such, the majority of people with hepatitis C do not discover that they harbor this virus until years or, often, decades later. Therefore, there are probably millions of peo-pie who currently have hepatitis C and have no idea that they are infected. However, if a person sees her doctor for an evaluation of symptoms, acute hepatitis C is usually detected from abnormal blood test results.
More information on Reclast Lawyers
Transaminases (AST and ALT) are often quite elevated initially. Levels of approximately 200 to 600 IU/1 can occur. (The normal range is approximately 0 to 45 IU/1.) Elevations in transaminases usually occur approximately six to eight weeks after infection with HCV (or within a range of two to twenty-six weeks). As the disease progresses, transaminases typically decrease. Transaminase levels often fluctuate between normal (or near normal) and elevated before permanently returning to normal. This fluctuation is a typical characteristic of hepatitis C. Persistent normalization of transaminases by six months usually indicates that acute hepatitis C has resolved. This occurs 15 to 25 percent of the time. If transaminases remain elevated (usually around two to three times normal) after this period or if the ALT levels elevate after a period of normalization, it usually indicates progression to chronic hepatitis C, which occurs approximately 60 to 85 percent of the time. Progression to chronic disease is always accompanied by an elevated HCV viral load.
Cholestatic liver enzymes (AP and GGTP) are usually only mildly elevated during acute hepatitis C—around two to three times normal—and bilirubin levels are usually normal. Around one-fourth of all people with acute hepatitis C become jaundiced. Even among these people, bilirubin levels usually normalize rapidly, usually within about one month.
Hepatitis C is limited to acute infection in around 15 to 40 percent of people. Typically, those people who suffered from the most symptoms (such as those who were jaundiced) are the ones most likely to clear the virus. These fortunate people have a complete resolution of symptoms, physical signs, and any LFT abnormalities due to infection with HCV. Also, their HCV RNA will permanently return to normal. These people do not develop chronic infection and. therefore, are not at risk for the long-term consequences of hepatitis C. Nor can they transmit HCV to others. However, eradicating one particular “strain” of HCV does not protect a person from becoming infected with other “strains” of HCV, or from other hepatitis viruses such as hepatitis A and B (see page 131 for a discussion of the different strains of HCV, also referred to as genotypes). Also, these people will never be allowed to donate blood, as they will always have the antibody for hepatitis C present in their blood.
Information from other sources on Reclast Lawyers
HCV is a virus that is very difficult to clear from the body. Thus, most people who become infected with HCV (acute hepatitis C) develop chronic disease (chronic hepatitis C). In fact, approximately 60 to 85 percent of infected people develop chronic hepatitis C. This is in stark contrast to the incidence of progression from acute to chronic in other forms of viral hepatitis. For example, hepatitis B progresses to chronic disease only about 5 percent of the time when the infection is acquired as an adult. And hepatitis A never leads to chronic disease. It appears that the immune system is not very efficient in clearing HCV. So, what makes HCV so formidable?
The genes that make up HCV can vary slightly from one strain to another. These different genetic variations of HCV are known as hepatitis C mutants, or quasispecies. The entire hepatitis C viral population that is present in a person infected with HCV is made up of a conglomerate of related, yet slightly different, HCV species. This virus population usually consists of one HCV mutant group that is strongest and dominant and numerous other HCV mutants that are weaker. These mutants are all similar in structure but differ slightly from one another. These slight variations in structure account for the fact that some HCV mutants are stronger and thus better equipped to tight the immune system than other HCV mutants. This is analogous to Darwin’s theory of evolution: the survival of the fittest.
The fact that HCV is such a resourceful and cunning virus probably accounts for why most people progress to chronic disease. When HCV is being attacked by the immune system during the acute infection, it can mutate into a stronger quasispecies variant. In this manner, HCV is able to outwit the body’s immune system and thwart its attempts to eradicate it. Thus, HCV tricks the body’s immune surveillance and escapes eradication, allowing for progression to chronic disease. This partly explains why long-term response rates to therapy with interferon, although getting much better, are still not 100 percent successful. It also may explain why it is so difficult to create a vaccination against HCV.
Certain factors have been identified as being predictive of which people are most likely to progress to chronic disease (that is, least likely to clear acute HCV).
Our use of the term or terms Reclast Lawyers is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.
To keep up to date on Reclast Lawyers visit our site often.
eople who work in a hospital or other healthcare facility (e.g., doctor’s office, medical labs, blood bank), as well as public-safety and emergency medical workers, are at risk for contracting HCV while on the job, through a needle stick or mucosal exposure (exposure to the mucus-secreting membranes that line a body cavity and communicate with the exterior, such as the inside of the mouth, nose, lips, and vagina) to the blood of an infected person. There is approximately a 2 percent chance of becoming infected with HCV after exposure to the blood of an HCV- positive person. However, the likelihood of contracting HCV ranges between 0 to 10 percent, based on a variety of factors. First, the higher the person’s HCV viral load (the amount of viral particles per milliliters of blood) at the time of the incident, the higher the risk of acquiring the virus. HCV viral loads (HCV RNA) greater than 500,000 lU/ml increase the likelihood of transmission. Second, the type of body tissue exposure influences the likelihood of transmission. The chance of transmission increases with exposure to mucous membranes, such as an eye splash (blood splashing into someone’s eye), and is the highest if there was exposure to breaks in the skin, such as an open wound or sore. HCV-infected blood on someone’s intact skin has never been reported as a cause of HCV iniec- tion. Third, the longer HCV is outside of the infected person’s body, the less chance there is of acquiring the virus. For example, HCV-infected blood from a test lube or lying on a surface is less infectious than HCV-infected blood coming directly from a person’s body. This is because the level of HCV infectivity (the level of HCV RNA in blood) declines once it is outside the infected person. Finally, the type of instrument that a person was stuck with is relevant to the likelihood of acquiring HCV. For example, sticking oneself with a solid needle (such as a suture needle) carries a relatively low chance of HCV acquisition since these needles can hold only a small volume of blood. In contrast, sticking oneself with a hollow-bore needle (such as a needle used in drawing blood), which can hold a large volume of HCV-infected blood, carries a higher risk of HCV acquisition.